English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Chronic myeloid leukemia (CML) was a fatal disease for almost all patients until the introduction of allogeneic stem cell transplantation (SCT) and of interferon-alfa (IFNα). However, these were of benefit only for a minority of patients.[1][1] The targeted therapies, first imatinib, then the other

Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden